Millennium’s CTO Michael Pavia says the company employs its homemade DNA chips to streamline just about every area of the drug discovery process.
By Peter Gwynne
Michael Pavia has a mission. He wants to cut the cost of bringing new drugs to market by 50 percent. As chief technology officer of Millennium Pharmaceuticals, he is well placed to do so.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
